Massachusetts General Hospital
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Massachusetts General Hospital sits in the top decile of US sponsors by registered trial count (#4 of 15,751 sponsors by registered trial count).
Massachusetts General Hospital: 2,032 sponsored US clinical trials, 336 recruiting.
Massachusetts General Hospital sponsors 2,032 registered US clinical trials on ClinicalTrials.gov, 336 of them currently recruiting, and 1,284 completed. 240 of these trials are in Phase 3-4 (later-stage) and 515 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Depression, with 29 trials.
Top-decile sponsor footprint
Massachusetts General Hospital ranks in the top decile of sponsors by registered trial count (#4 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
2,032 total, page 35 of 41
RAD001 and Lenalidomide in the Treatment of Subjects With Relapsed and Relapsed/Refractory Multiple Myeloma
NCT00729638
Ethylvinyl Acetate (EVA) Vaginal Ring Delivery System Study
NCT00706784
Intervention to Reduce Stress in 0-5 Year Olds With Burns
NCT00844896
Efficacy and Safety Study of a Combination Product [Drug:BCI-024 (Buspirone) and Drug:BCI-049 (Melatonin)] to Treat Major Depressive Disorder (MDD)
NCT00705003
Comprehensive Cardiothoracic Dual Source CT for the Early Triage of Patients With Acute Chest Pain
NCT01067456
Ultrasound-Guided Block of the Lateral Femoral Cutaneous Nerve in Pediatric Patients
NCT01500655
Cardiovascular Study of Lisdexamfetamine in Healthy and Hypertensive Attention Deficit Hyperactivity Disorder Adults
NCT00753012
Myocardial Stress Perfusion Imaging With Dual Source CT
NCT00853671
Validation of Biomarkers in Amyotrophic Lateral Sclerosis (ALS)
NCT00677768
Carboplatin, Abraxane, and Bevacizumab in Previously Untreated Patients With Advanced Non-Small Cell Lung Cancer
NCT00642759
Memory Reconsolidation Blockade as a Novel Intervention for Nicotine Dependence
NCT00916721
Exploring a Potential Blood Test to Diagnose Major Depressive Disorder
NCT00705185
Infant Nutrition and Risk of Celiac Disease
NCT00819819
Perioperative Panitumumab and Epirubicin, Oxaliplatin and Xeloda (EOX) in Patients With Gastroesophageal Adenocarcinoma
NCT00667420
Stress Reduction Techniques and Anxiety: Therapeutic and Neuroendocrine Effects
NCT01033851
Cognitive Behavioral Therapy (CBT) for Adherence and Depression in Type 1 Diabetes
NCT01527981
A 12-Week, Placebo Controlled Trial of Ziprasidone as Monotherapy for Major Depressive Disorder
NCT00555997
Study of Memantine Augmentation in Severe Obsessive-Compulsive Disorder
NCT00869505
Improving Faculty's Ability to Speak Up to Others in the Operating Room
NCT02170818
Ranibizumab for Neurofibromas Associated With Neurofibromatosis 1
NCT00657202
Comparison of the Efficiency of Mouth-to-nose Breathing With Mouth-to-mouth Breathing
NCT00785447
Coenzyme Q10 in Huntington's Disease (HD)
NCT00608881
Study of Maca Root to Treat Sexual Dysfunction Associated With the Treatment Regimen for Bipolar Disorder in Females
NCT00575328
Tai Chi Training for Treating Depressed Chinese Americans
NCT01263730
The Oral Contraceptive Pill for Premenstrual Worsening of Depression
NCT00633360
A Study of Varenicline for Prevention of Relapse to Smoking in Patients With Schizophrenia or Bipolar Disorder
NCT00621777
A Maintenance Program for the Be Fit Employee Wellness Program
NCT00707577
Secretin Enhanced MRCP for Evaluation of Pancreatic Duct in Pediatric Population
NCT00621283
Secretin Enhanced MRCP for Evaluation of the Known or Suspected Intraductal Papillary Mucinous Neoplasms of the Pancreas
NCT00621556
Secretin Enhanced Multidetector CT Pancreatography for Evaluation of Known or Suspected Chronic Pancreatitis
NCT00620919
Efficacy and Safety of Topiramate in the Treatment of Sleep-Related Eating Disorder
NCT00606411
Ramelteon as an Adjunct Therapy in Non-Diabetic Patients With Schizophrenia
NCT00595504
Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant
NCT00513474
Smoking Cessation Intervention for Thoracic Patients
NCT00580398
Comparison of Two Behavioral Treatments for Stress Reduction
NCT00625807
Validation of a New Device to Measure Neuromuscular Disease Progression
NCT00606918
Comparison of DSCT With IB-IVUS and Angiography in the Assessment of Coronary Artery Disease
NCT00622167
Study of Maca Root for the Treatment of Antidepressant-Induced Sexual Dysfunction in Females
NCT00568126
Creatine Safety and Tolerability in Premanifest HD: PRECREST
NCT00592995
Safety and Effectiveness Study of Maca Root to Treat Antidepressant-Induced Sexual Dysfunction
NCT00181961
Erlotinib in Patients With Resected, Early Stage NSCLC With Confirmed Mutations in the EGFR
NCT00567359
Peripheral Venous Oxygen Saturation and Biomarkers to Estimate Cardiac Output and Filling Pressures in Heart Failure
NCT00595738
Cognitive Deficits in Major Depressive Disorder and Bipolar Disorder, Depressed Type: Prevalence and Improvement With Treatment of Depressive Symptoms
NCT00844974
Effectiveness of Vitamin Supplementation in Treating People With Residual Symptoms of Schizophrenia
NCT00611806
Neoadjuvant Accelerated Short Course Radiation Therapy With Proton Beam and Capecitabine for Resectable Pancreatic Cancer
NCT00438256
Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-risk Patients With Metastatic Renal Cell Carcinoma
NCT00556049
Pilot Study of Imatinib Mesylate to Treat Nephrogenic Systemic Fibrosis
NCT00677092
Omega-3 Fatty Acid Adjunctive to Open-Label Aripiprazole for the Treatment of Bipolar Disorder in Children and Adolescents
NCT00592683
Breast Cancer Detection: Comparison of Breast Tomosynthesis and Conventional Mammography
NCT01669148
Determination of Dosing and Frequency of BCG Administration to Alter T-Lymphocyte Profiles in Type I Diabetics
NCT00607230
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 226 |
| Phase 2 | 289 |
| Phase 3 | 58 |
| Phase 4 | 182 |
Therapeutic Areas
What is open in the Massachusetts General Hospital pipeline
336 recruiting of 2,032 indexed (17% open); 1,284 completed (63%).
Phase mix: 240 late (III/IV) vs 515 early (I/II) (early-phase heavy).
Top condition: Depression (29 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.